Company: PSTV
Filing Date: 2025-11-17
Form Type: 8-K
Source: 0001193125-25-283935
Chunk: 1

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-11-17
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01      Other Events.  

As previously disclosed, on May 16, 2025, the Company received notice (the “ Notification Letter”) from the Nasdaq Staff that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the Minimum Bid Price Requirement. The Notification Letter stated that the Company had 180 days, or until November 12, 2025, to demonstrate its compliance with the Minimum Bid Price Requirement.

On November 13, 2025, the Company received a second letter from the Nasdaq Staff advising that the Company had been granted an additional 180 calendar days, or until May 11, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A).

The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement. Specifically, the Company has confirmed to The Nasdaq Stock Market LLC (“ Nasdaq”) that, if necessary, it will implement a reverse stock split of its outstanding common stock to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day additionalcompliance period or maintain compliance with the other Nasdaq listing requirements.